Investors Buy High Volume of BioNTech Call Options (NASDAQ:BNTX)

BioNTech SE (NASDAQ:BNTX) was the recipient of some unusual options trading on Wednesday. Traders bought 2,346 call options on the stock. This is an increase of 59% compared to the typical volume of 1,477 call options.

BioNTech Stock Down 3.2 %

Shares of BNTX opened at $99.00 on Friday. The company’s 50-day moving average price is $90.83 and its 200 day moving average price is $95.91. BioNTech has a 12-month low of $85.21 and a 12-month high of $125.83. The company has a current ratio of 11.38, a quick ratio of 11.16 and a debt-to-equity ratio of 0.01. The firm has a market cap of $23.54 billion, a P/E ratio of 198.00 and a beta of 0.25.

BioNTech (NASDAQ:BNTX) last released its quarterly earnings results on Wednesday, March 20th. The company reported $2.05 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.64 by ($0.59). The company had revenue of $1.59 billion during the quarter, compared to analysts’ expectations of $2.04 billion. BioNTech had a net margin of 4.01% and a return on equity of 0.55%. On average, sell-side analysts forecast that BioNTech will post -1.99 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Cambridge Investment Research Advisors Inc. grew its holdings in shares of BioNTech by 3.9% in the third quarter. Cambridge Investment Research Advisors Inc. now owns 3,980 shares of the company’s stock valued at $432,000 after purchasing an additional 148 shares in the last quarter. Raymond James & Associates raised its stake in shares of BioNTech by 5.6% in the third quarter. Raymond James & Associates now owns 5,579 shares of the company’s stock valued at $606,000 after acquiring an additional 298 shares in the last quarter. EverSource Wealth Advisors LLC boosted its holdings in BioNTech by 186.0% in the third quarter. EverSource Wealth Advisors LLC now owns 855 shares of the company’s stock valued at $93,000 after purchasing an additional 556 shares during the period. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. grew its stake in BioNTech by 11.4% during the 3rd quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 2,725 shares of the company’s stock worth $296,000 after purchasing an additional 279 shares in the last quarter. Finally, Fox Run Management L.L.C. purchased a new stake in BioNTech during the 3rd quarter worth about $861,000. 15.52% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

BNTX has been the subject of a number of recent research reports. HC Wainwright increased their price objective on shares of BioNTech from $107.00 to $113.00 and gave the company a “buy” rating in a report on Wednesday, May 8th. The Goldman Sachs Group reduced their price objective on BioNTech from $113.00 to $100.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 28th. BMO Capital Markets dropped their target price on BioNTech from $123.00 to $122.00 and set an “outperform” rating for the company in a report on Tuesday, May 7th. Evercore ISI started coverage on BioNTech in a research note on Tuesday, May 14th. They issued an “inline” rating and a $100.00 target price for the company. Finally, UBS Group lowered their price target on shares of BioNTech from $110.00 to $101.00 and set a “neutral” rating on the stock in a research report on Wednesday, March 27th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and three have given a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $111.70.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.